# Lakefront Biotherapeutics Sells Preclinical Cell Therapy Programs to Armed Cell Therapeutics

- URL: https://stocks.freetheai.org/news/lakefront-biotherapeutics-sells-preclinical-cell-therapy-programs-to-armed-cell-ae6bc8
- Published: 2026-10-14T20:01:00Z
- Category: company_news; sentiment: neutral; impact: medium
- Symbols: [EURONEXT:LKFT](https://stocks.freetheai.org/symbols/EURONEXT-LKFT)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Lakefront Biotherapeutics NV (EURONEXT:LKFT) has completed the sale of its early-stage preclinical cell therapy pipeline to Armed Cell Therapeutics BV. Under the terms of the agreement, Lakefront received an upfront payment of 8 million euros and remains eligible for up to $230 million in potential milestone payments, alongside low-single-digit royalties on future sales.

The transaction substantially completes Lakefront's previously announced plan to wind down its legacy cell therapy business. The transferred preclinical assets include multi-targeting and armed CAR-T constructs designed to address treatment resistance in blood cancers and solid tumors. Armed Cell Therapeutics, a Belgium-based biotechnology company formed by experienced industry executives, will independently advance the assets.

Following the sale, Lakefront is focusing its resources on its clinical-stage portfolio in immunology and inflammation. Investors will monitor progress on gamgertamig, its potential first-in-class T-cell engager candidate for autoimmune diseases, supported by its cash position and pipeline.

## Key points

- Lakefront Biotherapeutics sold its preclinical CAR-T cell therapy programs to Armed Cell Therapeutics.
- The deal includes an 8 million euro upfront payment and up to $230 million in potential milestone payments.
- Lakefront is also eligible to receive low-single-digit royalties on potential future program sales.
- The transaction substantially completes Lakefront's wind-down of its legacy cell therapy activities.

## Questions and answers

### What did Lakefront Biotherapeutics sell to Armed Cell Therapeutics?

Lakefront Biotherapeutics sold its preclinical cell therapy pipeline, including multi-targeting and armed CAR-T constructs for cancer research.

### What are the financial terms of the Lakefront Biotherapeutics deal?

Lakefront received an upfront payment of 8 million euros, with potential for up to $230 million in future milestone payments and low-single-digit royalties.

### Why did Lakefront Biotherapeutics divest its cell therapy assets?

The sale substantially completes Lakefront's strategic wind-down of its legacy cell therapy business so it can focus on immunology and inflammation programs.